Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'

被引：2
|
作者：
Tougeron, D. [1 ]
Laurent-Puig, P. [2 ]
Zaanan, A. [2 ,3 ]
机构：
[1] Univ Poitiers Hosp, Dept Gastroenterol, Poitiers, France
[2] INSERM, UMR S775, Paris, France
[3] European Georges Pompidou Univ Hosp, AP HP, Dept Gastroenterol & Digest Oncol, Paris, France
来源：
BRITISH JOURNAL OF CANCER | 2014年 / 111卷 / 12期
关键词：
CIRCULATING MUTANT-DNA; ANTI-EGFR THERAPY; K-RAS MUTATIONS; ACQUIRED-RESISTANCE; CETUXIMAB; PCR;
D O I：
10.1038/bjc.2014.114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2379 / 2380
页数：3
相关论文
共 50 条
  • [1] Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
    D Tougeron
    P Laurent-Puig
    A Zaanan
    British Journal of Cancer, 2014, 111 : 2379 - 2380
  • [2] Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
    K-L G Spindler
    N Pallisgaard
    R F Andersen
    A Jakobsen
    British Journal of Cancer, 2014, 111 : 2380 - 2380
  • [3] Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
    Spindler, K-L G.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2380 - 2380
  • [4] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    Spindler, K. G.
    Appelt, A. L.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3067 - 3072
  • [5] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    K G Spindler
    A L Appelt
    N Pallisgaard
    R F Andersen
    A Jakobsen
    British Journal of Cancer, 2013, 109 : 3067 - 3072
  • [6] KRAS mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    Spindler, K.
    Appelt, A. L.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S11 - S11
  • [7] Microenvironment targets in KRAS-mutated metastatic colorectal cancer
    Marchio, Serena
    Bartolini, Alice
    Cardaci, Sabrina
    Soster, Marco
    Corti, Giorgio
    Lamba, Simona
    Bussolino, Federico
    Cora', Davide
    Nicolantonio, Federica D.
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Advanced therapies on BRAF-mutated and KRAS-mutated metastatic colorectal cancer
    LI Zi-nan
    YU Li-feng
    WANG Jia-qi
    NIU Yan-xin
    WANG Xin-yu
    ZHAO Lin
    中国药理学与毒理学杂志, 2019, (10) : 883 - 883
  • [9] Sotorasib in KRAS-Mutated Colorectal Cancer
    Fojo, Tito
    Fakih, Marwan G.
    Chao, Joseph
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (02): : 186 - 187
  • [10] MicroRNA signature associated with KRAS-mutated colorectal cancer
    Andreoiu, O-M
    Dobre, M.
    Pirvu, I-R
    Vasilescu, F.
    Herlea, V.
    Becheanu, G.
    VIRCHOWS ARCHIV, 2017, 471 : S161 - S162
12345